Reciprocal regulation of miR‐206 and IL‐6/STAT3 pathway mediates IL6‐induced gefitinib resistance in EGFR‐mutant lung cancer cells

Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations

(2018) Tomoki Tamura et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib

(2018) Jinyao Wang et al.   CELL BIOLOGY INTERNATIONAL

miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT

(2018) Demin Jiao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

(2018) Tatsuya Nagano et al.   Cells

Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE 2 /β-catenin signalling pathway

(2017) Dehai Che et al.   MOLECULAR IMMUNOLOGY

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

(2017) Mei Zhou et al.   Nature Communications

Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c

(2017) Michiko Narita et al.   PLoS One

High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer

(2017) Estela Maria Silva et al.   PLoS One

Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells

(2016) Weibing Wu et al.   FEBS Journal

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

(2016) Chengguang Zhao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth

(2016) Yan-Xia Zhang et al.   Cell Death & Disease

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

(2016) Ourania Romanidou et al.   Therapeutic Advances in Medical Oncology

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

(2016) Fei Meng et al.   Frontiers in Genetics

The emerging role of microRNAs in resistance to lung cancer treatments

(2015) Lauren MacDonagh et al.   CANCER TREATMENT REVIEWS

Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers

(2015) Ruth Rodriguez-Barrueco et al.   GENES & DEVELOPMENT

Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3

(2015) JIE TANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs

(2015) Chirag Nepal et al.   NUCLEIC ACIDS RESEARCH

Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma

(2015) K-Y Lin et al.   ONCOGENE

Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells

(2015) Wei Cao et al.   Scientific Reports

Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma

(2015) Huamin Wang et al.   OncoImmunology

Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells

(2014) Jui-Chieh Chen et al.   ANNALS OF SURGICAL ONCOLOGY

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

(2014) L. Li et al.   CLINICAL CANCER RESEARCH

Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6

(2014) Che Dehai et al.   IMMUNOLOGY LETTERS

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma

(2013) Tasnim Ara et al.   CANCER RESEARCH

The Role of miRNAs in Regulating Gene Expression Networks

(2013) Allan M. Gurtan et al.   JOURNAL OF MOLECULAR BIOLOGY

Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells

(2013) Tuoen Liu et al.   LEUKEMIA RESEARCH

Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition

(2013) L Guo et al.   ONCOGENE

miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells

(2013) Gang Chen et al.   PLoS One

Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma

(2012) K. Sugimura et al.   CLINICAL CANCER RESEARCH

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Molecular Basis for Interaction of let-7 MicroRNAs with Lin28

(2011) Yunsun Nam et al.   CELL

Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells

(2011) K. Rai et al.   MOLECULAR CANCER THERAPEUTICS

EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

(2011) Michela Garofalo et al.   NATURE MEDICINE

MicroRNA-206 Is Associated With Invasion and Metastasis of Lung Cancer

(2010) Xiaochen Wang et al.   Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology

MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer

(2010) Miao Zhong et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Interleukin-6 in bone metastasis and cancer progression

(2010) Tasnim Ara et al.   EUROPEAN JOURNAL OF CANCER

The widespread regulation of microRNA biogenesis, function and decay

(2010) Jacek Krol et al.   NATURE REVIEWS GENETICS

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammation and Cancer: IL-6 and STAT3 Complete the Link

(2009) Jacqueline Bromberg et al.   CANCER CELL

Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors

(2009) Heehyoung Lee et al.   CANCER CELL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

Posttranscriptional Regulation of miRNAs Harboring Conserved Terminal Loops

(2008) Gracjan Michlewski et al.   MOLECULAR CELL

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

(2008) F. Pichiorri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA